Chiron Investment Management LLC Has $732,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Chiron Investment Management LLC grew its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 90.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,074 shares of the biotechnology company's stock after acquiring an additional 984 shares during the quarter. Chiron Investment Management LLC's holdings in United Therapeutics were worth $732,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in UTHR. Signaturefd LLC lifted its holdings in shares of United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after purchasing an additional 30 shares during the period. Parallel Advisors LLC raised its position in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after acquiring an additional 30 shares during the last quarter. Great Lakes Advisors LLC raised its position in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after purchasing an additional 31 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after acquiring an additional 33 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock valued at $1,761,000 after purchasing an additional 39 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $955,319.67. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company's stock, valued at $11,261,606.58. The trade was a 23.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 80,500 shares of company stock worth $27,849,960. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $0.46 during mid-day trading on Friday, reaching $284.73. 302,945 shares of the company traded hands, compared to its average volume of 453,066. The stock has a fifty day simple moving average of $317.98 and a 200-day simple moving average of $349.16. United Therapeutics Co. has a fifty-two week low of $233.28 and a fifty-two week high of $417.82. The firm has a market cap of $12.79 billion, a PE ratio of 12.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the firm earned $4.36 earnings per share. As a group, analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on UTHR shares. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday. UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.